Apparent diffusion coefficients (ADC) in response assessment of transarterial radioembolization (TARE) for liver metastases of neuroendocrine tumors (NET): a feasibility study

التفاصيل البيبلوغرافية
العنوان: Apparent diffusion coefficients (ADC) in response assessment of transarterial radioembolization (TARE) for liver metastases of neuroendocrine tumors (NET): a feasibility study
المؤلفون: Homeira Karim, Harun Ilhan, Christine Schmid-Tannwald, Karla-Maria Treitl, Jens Ricke, Maria Katharina Ingenerf, Nicola Fink
المصدر: Acta radiologica (Stockholm, Sweden : 1987). 63(7)
سنة النشر: 2021
مصطلحات موضوعية: medicine.medical_specialty, Tare weight, medicine.medical_treatment, Neuroendocrine tumors, Transarterial Radioembolization, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, Radiology, Nuclear Medicine and imaging, Retrospective Studies, Radiological and Ultrasound Technology, business.industry, Liver Neoplasms, General Medicine, medicine.disease, Embolization, Therapeutic, Radiation therapy, Response assessment, Neuroendocrine Tumors, Diffusion Magnetic Resonance Imaging, Treatment Outcome, 030220 oncology & carcinogenesis, Feasibility Studies, Radiology, business
الوصف: Background In patients with hepatic neuroendocrine tumors (NETs) locoregional therapies such as transarterial radioembolization (TARE) are increasingly applied. Response evaluation remains challenging and previous studies assessing response with diffusion-weighted imaging (DWI) have been inconclusive. Purpose To perform a feasibility study to evaluate if response assessment with quantitative apparent diffusion coefficient (ADC) in patients with liver metastases of NETs after TARE will be possible. Material and Methods Retrospectively, 43 patients with 120 target lesions who obtained abdominal magnetic resonance imaging (MRI) with DWI 39±28 days before and 74±46 days after TARE were included. Intralesional ADC (ADCmin, ADCmax, and ADCmean) were measured for a maximum number of three lesions per patient on baseline and post-interventional DWI. Tumor response was categorized according to RECIST 1.1 and mRECIST. Results TARE resulted in partial remission (PR) in 23% (63%), in stable disease (SD) in 73% (23%), in progressive disease (PD) in 5% (7%) and in complete response (CR) in 0% (1%) according to RECIST 1.1 (mRECIST, respectively). ADC values increased significantly ( Pmean values were slightly higher for responders compared to non-responders ( PConclusion ADC values seem to represent an additional marker for treatment response evaluation after TARE in patients with secondary hepatic NET. A conclusive study seems feasible though patient-based evaluation and overall survival and progression free survival as alternate primary endpoints should be considered.
تدمد: 1600-0455
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61698072823c703b81bc6798a2329b24Test
https://pubmed.ncbi.nlm.nih.gov/34225464Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....61698072823c703b81bc6798a2329b24
قاعدة البيانات: OpenAIRE